GRAL vs ILMN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GRAL and ILMN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GRAL and ILMN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

GRAIL, Inc. develops and sells the Galleri multi-cancer early detection (MCED) test, a blood draw that looks for DNA shed by tumors to screen for dozens of cancer types, including many (pancreatic, ovarian, esophageal, liver) that have no standard screening today. The company was originally incubated inside Illumina and became an independent public company after a court-ordered spin-off in 2024, and it now trades on Nasdaq under GRAL. Galleri is sold largely out-of-pocket and through employer and health-system channels while GRAIL pursues regulatory approval and broad insurance reimbursement.

Full GRAL guide

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen.

Full ILMN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GRAL drivers: Galleri volume and revenue growth; FDA approval pathway.
• ILMN drivers: Installed base and the consumables annuity; The NovaSeq X transition.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. For ILMN, competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GRAL if you believe its drivers more; ILMN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GRAL and ILMN guides.

GRAL. GRAIL trades on revenue growth and its cash runway rather than earnings, since it is deeply unprofitable while it scales Galleri. The roughly $823 million cash position against a trailing operating cash burn near $290 million a year implies a multi-year runway before any need to raise capital. The high price-to-sales multiple reflects investor expectations tied to FDA approval and future reimbursement, not present profitability.

ILMN. Illumina trades at a premium earnings multiple that reflects its platform dominance and consumables annuity, set against low-single-digit revenue growth and a slow-growing end market. Full-year 2025 revenue was about $4.34 billion, and the company guided fiscal 2026 to roughly $4.5 to $4.6 billion with operating margins recovering toward the low-to-mid 20s. All figures are approximate, tied to the June 2026 asOf date, and move with the share price and reported results; verify current numbers before relying on them.

Headline figures (approximate, JULY 2026): GRAL shows revenue (ttm) ~$156M, q1 2026 revenue (yoy) ~$40.8M (+28%), net loss (ttm) ~-$395M, cash & short-term investments ~$823M; ILMN shows revenue (fy2025) ~$4.34 billion (approximate, verify), 2026 revenue guidance ~$4.5-4.6 billion, ~4-6% growth (company guidance, verify), consumables mix Majority of revenue is recurring consumables (razor-and-blades; verify), non-gaap operating margin (2026 guide) ~23.3-23.5% (company guidance, verify).

GRAL and ILMN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GRAL and ILMN exposure against your real portfolio. It is not an investment adviser.